ClinicalTrials.gg
CompletedNCT01012973GALILEOUpdated Nov 3, 2014Results posted

Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Central Retinal Vein Occlusion (CRVO)

A Phase 3 interventional study of Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) and Sham treatment in Retinal Vein Occlusion, sponsored by Bayer. Completed at 73 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-11-03.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
177
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing aflibercept in Retinal Vein Occlusion — none open to participants now, none under way, none of them phase 3. aflibercept · Retinal Vein Occlusion.

Enrollment
4th of 21
177 · median 56
Started
2009
with 1 other
Phase 3
4 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
2 of 21
Bayer

Among the 21 studies testing aflibercept in Retinal Vein Occlusion, this one is the 4th largest by enrollment, is one of 2 that started in 2009, is one of 4 in phase 3, and was the 2nd registered.

Retinal Vein Occlusion

289 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

Browse Retinal Vein Occlusion studies →

Open to participants now

None of the 21 studies testing aflibercept in Retinal Vein Occlusion is open now. The open studies under Retinal Vein Occlusion, anywhere →

About aflibercept

aflibercept: first FDA approval 2011 (EYLEA), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 18 Retinal Vein Occlusion studies recruiting now, 13 (72%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing aflibercept in Retinal Vein Occlusion as a file.
02

Study summary

To determine the efficacy of vascular endothelial growth factor (VEGF) Trap-Eye injected into the eye on vision function in subjects with macular edema as a consequence of central retinal vein occlusion

03

Conditions studied

  • Retinal Vein Occlusion

Keywords

  • Macular Edema
  • Central Retinal Vein Occlusion
  • CRVO
  • VEGF Trap-Eye
  • best-corrected visual acuity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Center-involved macular edema secondary to central retinal vein occlusion (CRVO) for no longer than 9 months with mean central subfield thickness ≥ 250 μm on optical coherence tomography (OCT)
  • Adults ≥ 18 years
  • Early treatment diabetic retinopathy study (ETDRS) best corrected visual acuity (BCVA) of 20/40 to 20/320 (73 to 24 letters) in the study eye

Exclusion criteria

Exclusion Criteria:

  • Any prior treatment with anti-VEGF agents in the study eye (Pegaptanib sodium, anecortave acetate, bevacizumab, ranibizumab, etc.) or previous administration of systemic anti-angiogenic medications
  • Prior panretinal laser photocoagulation or macular laser photocoagulation in the study eye
  • CRVO disease duration > 9 months from date of diagnosis
  • Previous use of intraocular in the study eye or use of periocular corticosteroids in the study eye within the 3 months prior to Day 1
  • Iris neovascularization, vitreous hemorrhage, traction retinal detachment, or preretinal fibrosis involving the macula in either the study eye or fellow eye
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
177 participants (actual)

Study arms

  • Experimental
    Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

    Participants received a 2 mg dose of Intravitreal Aflibercept Injection (IAI) administered every 4 weeks from Day 1 through Week 20, later as often as every 4 weeks depending on the study retreatment criteria from Week 24 through Week 48. Follow-up phase: Participants on IAI, who continued the study, received 2 mg dose of IAI depending on the study retreatment criteria at Week 60 and 68.

    Biological: Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) · Other: Sham treatment

  • Sham comparator
    Sham treatment

    Participants received sham treatment administered every 4 weeks from Day 1 through Week 52. Follow-up phase: Participants on sham treatment, who switched to Intravitreal Aflibercept Injection (IAI), received a 2 mg dose of IAI at week 52 and depending on the study retreatment criteria at Week 60 and 68.

    Other: Sham treatment

Interventions

  • Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.

  • OtherSham treatment

    Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)

    Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. However, because this was assessed at the screening visit, subjects may have had a higher BCVA recorded at the baseline visit and would not have been excluded from the study.

    Time frame: Baseline and Week 24

  2. Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF

    Time frame: Baseline and Week 24

  3. Percentage of Participants Who Developed Neovascularization During the First 24 Weeks

    Formation of blood vessels in the anterior segment, optic disc, or elsewhere in the fundus up to Week 24

    Time frame: From baseline until Week 24

  4. Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF

    The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight

    Time frame: Baseline and Week 24

  5. Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF

    EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).

    Time frame: Baseline and Week 24

07

Results

Posted Nov 22, 2012

Participant flow

Participant flow — Overall Study
MilestoneAflibercept Injection First, Then Aflibercept InjectionSham Treatment First, Then Aflibercept Injection
Started10671
Participants received treatment10468
Fulfilled requirements of fas population10368
Completed week 24, from fas9757
Completed week 52, from fas9152
Completed9052
Not completed1619
Withdrew: Adverse event55
Withdrew: Lack of efficacy05
Withdrew: Lost to follow-up10
Withdrew: (overseas travel - indefinite period)10
Withdrew: Increase in vis. acuity, never injected01
Withdrew: Protocol violation52
Withdrew: Withdrawal by subject46

Outcome measures

PrimaryPercentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline and Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures
Percentage of participantsAflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham Treatment
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS Letter Score Compared With Baseline at Week 24 With Discontinued Participants Before Week 24 Evaluated as Failures60.222.1
Statistical analysis
  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) vs Sham Treatment · Cochran-Mantel-Haenszel · p = <.0001 · Cmh adjusted difference: 38.3 · 95% CI 24.4 to 52.1The estimate is calculated as Eylea minus Sham. A positive value shows Eylea showed a higher BCVA total score compared to Sham.
SecondaryChange From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)

Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 24 (= Acuity of 20/40 to 20/320) in the study eye; a higher score represents better functioning. However, because this was assessed at the screening visit, subjects may have had a higher BCVA recorded at the baseline visit and would not have been excluded from the study.

Time frame:
Baseline and Week 24
Reported as:
Mean · Letters correctly read
Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)
Letters correctly readAflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham Treatment
Change From Baseline in BCVA as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) Letter Score at Week 24 - Last Observation Carried Forward (LOCF)71.6 ± 17.154.3 ± 20.2
Statistical analysis
  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) vs Sham Treatment · ANOVA · p = <.0001 (As primary efficacy evaluation was significant, and this p-value was below significance level of two-sided \<.05, the fixed sequence testing did continue with next secondary endpoint.) · Difference in least square means: 14.7 · 95% CI 10.8 to 18.7The difference is calculated as Eylea minus Sham. A positive value indicates Eylea showed a higher change in BCVA total score until week 24 compared to Sham.
SecondaryChange From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF
Time frame:
Baseline and Week 24
Reported as:
Mean · microns
Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF
micronsAflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham Treatment
Change From Baseline in Central Retinal Thickness (CRT) at Week 24 - LOCF-448.58 ± 256.02-169.27 ± 224.72
Statistical analysis
  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) vs Sham Treatment · ANCOVA · p = <.0001 (As fixed sequence testing did reject nullhypothesis of change from baseline in BCVA until week 24, and this p-value was below significance level of two-sided \<.05, the fixed sequence testing did continue with next secondary endpoint.) · Difference in least square (ls) means: -239.42 · 95% CI -286.31 to -192.53The difference is calculated as Eylea minus Sham. A negative value indicates Eylea showed a higher reduction in change in central retinal thickness until week 24 compared to Sham.
SecondaryPercentage of Participants Who Developed Neovascularization During the First 24 Weeks

Formation of blood vessels in the anterior segment, optic disc, or elsewhere in the fundus up to Week 24

Time frame:
From baseline until Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Developed Neovascularization During the First 24 Weeks
Percentage of participantsAflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham Treatment
Any neovascularization2.94.4
Anterior segment neovascularization1.91.5
Neovascularization of the optic disc (NVD)0.00.0
Neovascularization elsewhere in the fundus (NVE)1.02.9
Statistical analysis
  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) vs Sham Treatment · Cochran-Mantel-Haenszel · p = 0.5947 (As fixed sequence testing did reject nullhypothesis of change from baseline in CRT until week 24, and this p-value was not below significance level of two-sided \<.05, the fixed sequence testing did end with this evaluation.) · Cmh adjusted difference: -1.5 · 95% CI -7.4 to 4.4Cochrane-Mantel-Haenszel test, stratified by region and baseline BCVA category.
SecondaryChange From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF

The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight

Time frame:
Baseline and Week 24
Reported as:
Mean · Scores on a scale
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF
Scores on a scaleAflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham Treatment
Change From Baseline in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score at Week 24 - LOCF7.46 ± 9.553.55 ± 9.74
Statistical analysis
  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) vs Sham Treatment · Difference in ls means: 4.2 · 95% CI 1.7 to 6.8As the fixed sequence of secondary endpoints stopped with proportion of neovascularizations developed until week 24, 95% confidence interval is only of descriptive nature.
SecondaryChange From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF

EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).

Time frame:
Baseline and Week 24
Reported as:
Mean · Scores on a scale
Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF
Scores on a scaleAflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham Treatment
Change From Baseline in European Five-dimensional Health Scale (EQ-5D) Score at Week 24 - LOCF0.029 ± 0.139-0.002 ± 0.195
Statistical analysis
  • Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321) vs Sham Treatment · Difference in ls means: 0.044 · 95% CI -0.002 to 0.09As the fixed sequence of secondary endpoints stopped with proportion of neovascularizations developed until week 24, 95% confidence interval is only of descriptive nature.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept Injection (Until Week 20)—8/104 (7.7%)52/104 (50%)
Sham Treatment (Until Week 20)—8/68 (11.8%)44/68 (64.7%)
Aflibercept Injection (Until Week 48)—14/97 (14.4%)66/97 (68%)
Sham Treatment (Until Week 48)—7/57 (12.3%)30/57 (52.6%)
Aflibercept Injection Continued (Until Week 68)—4/91 (4.4%)38/91 (41.8%)
Sham Treatment Then Aflibercept Injection (Until Week 68)—3/52 (5.8%)19/52 (36.5%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventAflibercept Injection (Until Week 20)Sham Treatment (Until Week 20)Aflibercept Injection (Until Week 48)Sham Treatment (Until Week 48)Aflibercept Injection Continued (Until Week 68)Sham Treatment Then Aflibercept Injection (Until Week 68)
Macular oedemaEye disorders0/1042/684/970/571/910/52
SyncopeNervous system disorders0/1040/681/972/570/910/52
Visual acuity reducedEye disorders0/1041/681/970/572/910/52
Aortic valve incompetenceCardiac disorders0/1040/680/970/570/911/52
Cardiac failureCardiac disorders0/1040/680/970/570/911/52
Coronary artery stenosisCardiac disorders0/1040/680/970/570/911/52
Diastolic dysfunctionCardiac disorders0/1040/680/970/570/911/52
Mitral valve incompetenceCardiac disorders0/1040/680/970/570/911/52
Femur fractureInjury, poisoning and procedural complications0/1040/680/970/570/911/52
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders0/1040/680/970/570/911/52
Most frequent other events
Showing 10 of 25
Most frequent other events
EventAflibercept Injection (Until Week 20)Sham Treatment (Until Week 20)Aflibercept Injection (Until Week 48)Sham Treatment (Until Week 48)Aflibercept Injection Continued (Until Week 68)Sham Treatment Then Aflibercept Injection (Until Week 68)
Macular oedemaEye disorders2/1049/6830/977/5717/912/52
NasopharyngitisInfections and infestations8/1046/6810/9711/574/912/52
Intraocular pressure increasedInvestigations9/1044/6814/972/572/911/52
Eye painEye disorders12/1043/686/972/571/910/52
Retinal haemorrhageEye disorders4/1046/6811/975/575/912/52
Retinal vascular disorderEye disorders6/1047/6810/972/570/912/52
Visual acuity reducedEye disorders2/1047/6810/971/577/911/52
Eye irritationEye disorders3/1047/684/971/571/912/52
Conjunctival haemorrhageEye disorders10/1043/683/970/579/913/52
Retinal exudatesEye disorders8/1045/684/973/570/910/52

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham TreatmentTotal
Mean60.0 ± 12.363.8 ± 13.361.5 ± 12.8
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham TreatmentTotal
Female453176
Male593796
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham TreatmentTotal
Hispanic or Latino415
Not Hispanic or Latino10066166
Unknown or Not Reported011
Baseline Best Corrected Visual Acuity (BCVA) letter scores
Baseline Best Corrected Visual Acuity (BCVA) letter scores(Letters correctly read)Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham TreatmentTotal
Mean53.5 ± 15.750.9 ± 15.452.5 ± 15.6
Number of participants with baseline retinal perfusion
Number of participants with baseline retinal perfusion(Participants)Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham TreatmentTotal
Perfused9054144
Nonperfused7714
Indeterminate7714
Baseline Retinal Thickness by Optical Coherence Tomography (OCT)
Baseline Retinal Thickness by Optical Coherence Tomography (OCT)(microns)Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham TreatmentTotal
Mean682.78 ± 233.36638.66 ± 224.69665.34 ± 230.33
Baseline intraocular pressure
Baseline intraocular pressure(mm Hg)Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham TreatmentTotal
Mean15.2 ± 2.814.4 ± 2.714.9 ± 2.8
Number of participants with time since Central retinal vein occlusion (CRVO) diagnosis
Number of participants with time since Central retinal vein occlusion (CRVO) diagnosis(Participants)Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)Sham TreatmentTotal
>= 2 months463379
< 2 months563591
Missing202

3 further baseline measures are reported on the registry.

08

Study locations

73 sites
  • Chatswood, New South Wales 2067, Australia
  • Parramatta, New South Wales 2150, Australia
  • Sydney, New South Wales 2000, Australia
  • Westmead, New South Wales 2145, Australia
  • East Melbourne, Victoria 3002, Australia
  • Nedlands, Western Australia 6009, Australia
  • Innsbruck, 6020, Austria
  • Linz, 4021, Austria
  • Vienna, 1090, Austria
  • Paris, Cedex 12 75557, France
  • Nantes, Cedex 1 44093, France
  • Bordeaux, 33000, France
  • Dijon, 21033, France
  • Marseille, 13008, France
  • Paris, 75015, France
  • Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Heidelberg, Baden-Wurttemberg 69120, Germany
  • Tübingen, Baden-Wurttemberg 72076, Germany
  • München, Bavaria 81675, Germany
  • Regensburg, Bavaria 93053, Germany
  • Hamburg, Free and Hanseatic City of Hamburg 20251, Germany
  • Darmstadt, Hesse 64297, Germany
  • Frankfurt am Main, Hesse 60596, Germany
  • Marburg, Hesse 35037, Germany
  • Göttingen, Lower Saxony 37075, Germany
  • Aachen, North Rhine-Westphalia 52074, Germany
  • Bonn, North Rhine-Westphalia 53105, Germany
  • Cologne, North Rhine-Westphalia 50924, Germany
  • Essen, North Rhine-Westphalia 45122, Germany
  • Münster, North Rhine-Westphalia 48145, Germany
  • Ludwigshafen am Rhein, Rhineland-Palatinate 67063, Germany
  • Mainz, Rhineland-Palatinate 55131, Germany
  • Homburg, Saarland 66421, Germany
  • Chemnitz, Saxony 09116, Germany
  • Dresden, Saxony 01307, Germany
  • Dresden, Saxony 06067, Germany
  • Leipzig, Saxony 04103, Germany
  • Kiel, Schleswig-Holstein 24105, Germany
  • Lübeck, Schleswig-Holstein 23538, Germany
  • Berlin, State of Berlin 13353, Germany
  • Budapest, 1089, Hungary
  • Budapest, 1106, Hungary
  • Budapest, 1133, Hungary
  • Debrecen, 4032, Hungary
  • Veszprém, 8200, Hungary
  • Zalaegerszeg, H-8900, Hungary
  • Ancona, 60126, Italy
  • Bari, 70124, Italy
  • Catania, 95123, Italy
  • Florence, 50134, Italy
  • Milan, 20122, Italy
  • Milan, 20132, Italy
  • Milan, 20157, Italy
  • Padova, 35128, Italy
  • Roma, 00133, Italy
  • Roma, 00198, Italy
  • Torino, 10122, Italy
  • Nagoya, Aichi-ken 466-8560, Japan
  • Nagoya, Aichi-ken 467-8602, Japan
  • Urayasu, Chiba 279-0021, Japan
  • Kyoto, Kyoto 606-8507, Japan
  • Suita, Osaka 565-0871, Japan
  • Chiyoda-ku, Tokyo 101-8309, Japan
  • Riga, 1002, Latvia
  • Riga, 1050, Latvia
  • Singapore, 119074, Singapore
  • Singapore, 168751, Singapore
  • Seongnam-si, Gyeonggido 463-707, South Korea
  • Incheon, 405-760, South Korea
  • Seoul, 110 744, South Korea
  • Seoul, 137-701, South Korea
  • Seoul, 138-736, South Korea
  • Seoul, South Korea
09

References and documents

Publications

  • Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R. VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase III GALILEO study. Br J Ophthalmol. 2013 Mar;97(3):278-84. doi: 10.1136/bjophthalmol-2012-301504. Epub 2013 Jan 7. PubMed 23298885 ↗
  • Korobelnik JF, Holz FG, Roider J, Ogura Y, Simader C, Schmidt-Erfurth U, Lorenz K, Honda M, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R; GALILEO Study Group. Intravitreal Aflibercept Injection for Macular Edema Resulting from Central Retinal Vein Occlusion: One-Year Results of the Phase 3 GALILEO Study. Ophthalmology. 2014 Jan;121(1):202-208. doi: 10.1016/j.ophtha.2013.08.012. Epub 2013 Sep 29. PubMed 24084497 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2009, a primary completion of Feb 2011 and a completion of Feb 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2012, 1 year 9 months after primary completion. A results delay was requested in Jan 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2009
First posted
Nov 13, 2009
Start
Oct 2009
Primary completionActual
Feb 2011
CompletionActual
Feb 2012
Results delay requested
Jan 26, 2012
Results first posted
Nov 22, 2012
Last update
Nov 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01012973
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 13, 2009
Start date
Oct 2009
Primary completion
Feb 2011
Completion
Feb 2012
Results posted
Nov 22, 2012
Last update
Nov 3, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion